Antonino Belfiore

List of Publications by Year
in descending order

196	12,819	17440 63	26613 107
papers	citations	h-index	g-index

203	203	203	12135
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. Endocrine Reviews, 2009, 30, 586-623.	20.1	889
2	Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age, and multinodularity. American Journal of Medicine, 1992, 93, 363-369.	1.5	444
3	Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved. Journal of Biological Chemistry, 2002, 277, 39684-39695.	3.4	413
4	The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Physiology and Biochemistry, 2008, 114, 23-37.	2.1	365
5	Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3713-3720.	3.6	299
6	Organ-Specific Autoimmunity: A 1986 Overview. Immunological Reviews, 1986, 94, 137-169.	6.0	274
7	Insulin Receptor Isoforms in Physiology and Disease: An Updated View. Endocrine Reviews, 2017, 38, 379-431.	20.1	270
8	Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene, 1999, 18, 2471-2479.	5.9	261
9	Increased Aggressiveness of Thyroid Cancer in Patients with Graves' Disease*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 830-835.	3.6	252
10	Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environmental Health Perspectives, 2012, 120, 1177-1182.	6.0	234
11	Insulin receptor and cancer. Endocrine-Related Cancer, 2011, 18, R125-R147.	3.1	233
12	The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer. Current Pharmaceutical Design, 2007, 13, 671-686.	1.9	230
13	A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 245-254.	3.6	216
14	BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 191-205.	3.1	210
15	Overexpression of the RON gene in human breast carcinoma. Oncogene, 1998, 16, 2927-2933.	5.9	190
16	Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells. Cancer Research, 2005, 65, 1849-1857.	0.9	188
17	HIF-1Î±/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Research, 2013, 15, R64.	5.0	173
18	The Role of Thyroid-Stimulating Antibodies of Graves' Disease in Differentiated Thyroid Cancer. New England Journal of Medicine, 1988, 318, 753-759.	27.0	155

#	Article	IF	Citations
19	The IGF system in thyroid cancer: new concepts. Journal of Clinical Pathology, 2001, 54, 121-124.	1.9	155
20	In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene, 2002, 21, 8240-8250.	5.9	150
21	The Role of Metformin in the Management of NAFLD. Experimental Diabetes Research, 2012, 2012, 1-13.	3.8	150
22	The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer, 1987, 60, 3096-3102.	4.1	146
23	Insulin Receptor Isoforms and Insulin-Like Growth Factor Receptor in Human Follicular Cell Precursors from Papillary Thyroid Cancer and Normal Thyroid. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 766-774.	3.6	130
24	Copper activates HIF-1Î±/GPER/VEGF signalling in cancer cells. Oncotarget, 2015, 6, 34158-34177.	1.8	128
25	FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID. Endocrinology and Metabolism Clinics of North America, 2001, 30, 361-400.	3.2	126
26	Evaluation of the fine needle aspiration biopsy in the preoperative selection of cold thyroid nodules. Cancer, 1991, 67, 2137-2141.	4.1	122
27	IGF and Insulin Receptor Signaling in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 381-406.	2.7	122
28	The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells. Frontiers in Endocrinology, 2014, 5, 10.	3.5	122
29	Graves' disease, thyroid nodules and thyroid cancer. Clinical Endocrinology, 2001, 55, 711-718.	2.4	119
30	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	5.9	119
31	Outcome of Differentiated Thyroid Cancer in Gravesâ€™ Patients1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2805-2809.	3.6	115
32	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. International Journal of Obesity, 2010, 34, 1255-1264.	3.4	111
33	Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Molecular and Cellular Endocrinology, 2010, 320, 162-170.	3.2	106
34	GPER Mediates Activation of HIF1Î±/VEGF Signaling by Estrogens. Cancer Research, 2014, 74, 4053-4064.	0.9	105
35	Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Scientific Reports, 2017, 7, 15992.	3.3	102
36	High frequency of cancer in cold thyroid nodules occurring at young age. European Journal of Endocrinology, 1989, 121, 197-202.	3.7	100

#	Article	IF	Citations
37	Outcome of Differentiated Thyroid Cancer in Graves' Patients. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2805-2809.	3.6	98
38	Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie, 1999, 81, 403-407.	2.6	96
39	Peroxisomal Proliferator-Activated Receptor-Î³ Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells. Endocrinology, 2006, 147, 4463-4475.	2.8	96
40	The G Protein-coupled Receptor 30 Is Up-regulated by Hypoxia-inducible Factor-1Î± (HIF-1Î±) in Breast Cancer Cells and Cardiomyocytes. Journal of Biological Chemistry, 2011, 286, 10773-10782.	3.4	93
41	PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer. PPAR Research, 2009, 2009, 1-18.	2.4	92
42	Overexpression of Insulin Receptors in Fibroblast and Ovary Cells Induces a Ligand-Mediated Transformed Phenotype. Molecular Endocrinology, 1991, 5, 452-459.	3.7	91
43	Detection of an Activating Mutation of the Thyrotropin Receptor in a Case of an Autonomously Hyperfunctioning Thyroid Insular Carcinoma1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 735-738.	3.6	91
44	Signaling Differences from the A and B Isoforms of the Insulin Receptor (IR) in 32D Cells in the Presence or Absence of IR Substrate-1. Endocrinology, 2003, 144, 2650-2658.	2.8	88
45	Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences, 2013, 14, 22933-22966.	4.1	88
46	Solitary Autonomously Functioning Thyroid Nodules and Iodine Deficiency*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 283-287.	3.6	87
47	Proinsulin Binds with High Affinity the Insulin Receptor Isoform A and Predominantly Activates the Mitogenic Pathway. Endocrinology, 2012, 153, 2152-2163.	2.8	87
48	Differential Gene Expression Induced by Insulin and Insulin-like Growth Factor-II through the Insulin Receptor Isoform A. Journal of Biological Chemistry, 2003, 278, 42178-42189.	3.4	86
49	Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene, 2013, 32, 678-688.	5.9	86
50	Detection of an Activating Mutation of the Thyrotropin Receptor in a Case of an Autonomously Hyperfunctioning Thyroid Insular Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 735-738.	3.6	85
51	GPER mediates the Egr-1 expression induced by 17Î²-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Research and Treatment, 2012, 133, 1025-1035.	2.5	84
52	The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discovery, 2017, 3, 17063.	4.7	79
53	Long-term outcome of patients with insular carcinoma of the thyroid. Cancer, 2002, 95, 2076-2085.	4.1	77
54	Insulin and Insulin-like Growth Factor II Differentially Regulate Endocytic Sorting and Stability of Insulin Receptor Isoform A. Journal of Biological Chemistry, 2012, 287, 11422-11436.	3.4	76

#	Article	IF	Citations
55	Cross-talk between GPER and growth factor signaling. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 50-56.	2.5	73
56	The Insulin Receptor: A New Target for Cancer Therapy. Frontiers in Endocrinology, 2011, 2, 93.	3.5	72
57	PPAR-Î³ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Frontiers in Endocrinology, 2017, 8, 31.	3.5	72
58	IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget, 2016, 7, 7683-7700.	1.8	69
59	Insulin Receptors in Breast Cancer. Annals of the New York Academy of Sciences, 1996, 784, 173-188.	3.8	66
60	Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1014-1021.	3.6	66
61	Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. European Journal of Cancer, 2007, 43, 1318-1327.	2.8	65
62	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2322-2328.	3.6	64
63	Differential Signaling Activation by Insulin and Insulin-Like Growth Factors I and II upon Binding to Insulin Receptor Isoform A. Endocrinology, 2009, 150, 3594-3602.	2.8	64
64	GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1Î²/IL1R1 response. Scientific Reports, 2016, 6, 24354.	3.3	64
65	Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. Journal of Endocrinological Investigation, 1995, 18, 134-139.	3.3	63
66	A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. International Journal of Biochemistry and Cell Biology, 2009, 41, 603-614.	2.8	63
67	New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cellular Signalling, 2012, 24, 1515-1521.	3.6	63
68	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2322-2328.	3.6	63
69	A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 245-254.	3.6	58
70	Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget, 2015, 6, 16084-16105.	1.8	57
71	GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget, 2016, 7, 94-111.	1.8	57
72	Relation between steroid receptor status and body weight in breast cancer patients. European Journal of Cancer, 1992, 28, 112-115.	2.8	54

#	Article	IF	Citations
73	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. Molecular Endocrinology, 2012, 26, 1603-1616.	3.7	53
74	Metformin Inhibits Androgen-Induced IGF-IR Up-Regulation in Prostate Cancer Cells by Disrupting Membrane-Initiated Androgen Signaling. Endocrinology, 2014, 155, 1207-1221.	2.8	50
75	Research Resource: New and Diverse Substrates for the Insulin Receptor Isoform A Revealed by Quantitative Proteomics After Stimulation With IGF-II or Insulin. Molecular Endocrinology, 2011, 25, 1456-1468.	3.7	48
76	Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 258-265.	3.6	48
77	GPER Mediates Cardiotropic Effects in Spontaneously Hypertensive Rat Hearts. PLoS ONE, 2013, 8, e69322.	2.5	48
78	Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biology, 2014, 35, 82-90.	3.6	47
79	In SituEvidence of Neoplastic Cell Phagocytosis by Macrophages in Papillary Thyroid Cancer¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1615-1620.	3.6	46
80	Activation of the Hepatocyte Growth Factor (HGF)-MetSystem in Papillary Thyroid Cancer: Biological Effects of HGF in Thyroid Cancer Cells Depend onMetExpression Levels. Endocrinology, 2004, 145, 4355-4365.	2.8	45
81	A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget, 2015, 6, 10825-10839.	1.8	44
82	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. PLoS ONE, 2013, 8, e83832.	2.5	43
83	GPER, IGFâ€IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancerâ€associated fibroblasts. Molecular Carcinogenesis, 2017, 56, 580-593.	2.7	43
84	The IL1Î²-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of Experimental and Clinical Cancer Research, 2020, 39, 153.	8.6	43
85	IGFâ€II Binding to Insulin Receptor Isoform A Induces a Partially Different Gene Expression Profile from Insulin Binding. Annals of the New York Academy of Sciences, 2004, 1028, 450-456.	3.8	42
86	Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cellular Signalling, 2014, 26, 1466-1475.	3.6	42
87	Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Frontiers in Endocrinology, 2015, 6, 30.	3.5	42
88	Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer. Molecular and Cellular Endocrinology, 2017, 457, 57-72.	3.2	42
89	Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?. Frontiers in Endocrinology, 2017, 8, 314.	3.5	42
90	Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 559-572.	3.4	42

#	Article	IF	Citations
91	Role of Cyclic AMP Response Elementâ€“Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells. Cancer Research, 2009, 69, 7270-7277.	0.9	41
92	GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression. Cells, 2019, 8, 223.	4.1	41
93	In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 132-139.	2.6	40
94	Recent advances on the stimulatory effects of metals in breast cancer. Molecular and Cellular Endocrinology, 2017, 457, 49-56.	3.2	39
95	Sortilin Regulates Progranulin Action in Castration-Resistant Prostate Cancer Cells. Endocrinology, 2015, 156, 58-70.	2.8	38
96	DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. Endocrine-Related Cancer, 2019, 26, 197-214.	3.1	38
97	Relationship between high prolactine levels and migraine attacks in patients with microprolactinoma. Journal of Headache and Pain, 2008, 9, 103-107.	6.0	37
98	GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocrine-Related Cancer, 2014, 21, 739-753.	3.1	37
99	Interleukin-4 Stimulates Papillary Thyroid Cancer Cell Survival: Implications in Patients with Thyroid Cancer and Concomitant Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2880-2889.	3.6	35
100	17Î²-Estradiol Up-regulates the Insulin-like Growth Factor Receptor through a Nongenotropic Pathway in Prostate Cancer Cells. Cancer Research, 2007, 67, 8932-8941.	0.9	35
101	Ligand-Mediated Endocytosis and Trafficking of the Insulin-Like Growth Factor Receptor I and Insulin Receptor Modulate Receptor Function. Frontiers in Endocrinology, 2014, 5, 220.	3.5	35
102	Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Oncotarget, 2016, 7, 52710-52728.	1.8	35
103	Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells. Oncotarget, 2017, 8, 43248-43270.	1.8	35
104	Neural Network Analysis for Evaluating Cancer Risk in Thyroid Nodules with an Indeterminate Diagnosis at Aspiration Cytology: Identification of a Low-Risk Subgroup. Thyroid, 2004, 14, 1065-1071.	4.5	33
105	Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. Endocrine, 2017, 58, 115-123.	2.3	33
106	COVID-19 and Diabetes: The Importance of Controlling RAGE. Frontiers in Endocrinology, 2020, 11, 526.	3.5	33
107	HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. European Journal of Cancer, 2010, 46, 1919-1926.	2.8	32
108	A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models. DMM Disease Models and Mechanisms, 2015, 8, 1237-46.	2.4	32

#	Article	IF	Citations
109	De novo HLA Class II and enhanced HLA Class I molecule expression in SV40 transfected human thyroid epithelial cells. Journal of Autoimmunity, 1991, 4, 397-414.	6.5	31
110	Effect of TSH in human thyroid cells: Evidence for both mitogenic and antimitogenic effects. Journal of Cellular Biochemistry, 1992, 49, 231-238.	2.6	31
111	Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Molecular Endocrinology, 1996, 10, 1318-1326.	3.7	31
112	Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. Cancers, 2010, 2, 233-261.	3.7	30
113	Role of c-Abl in Directing Metabolic versus Mitogenic Effects in Insulin Receptor Signaling. Journal of Biological Chemistry, 2007, 282, 26077-26088.	3.4	29
114	Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1168-E1178.	3.6	29
115	The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis. Cells, 2020, 9, 622.	4.1	28
116	Induction of intercellular adhesion molecule-1 but not of lymphocyte function-associated antigen-3 in thyroid follicular cells. Journal of Autoimmunity, 1992, 5, 119-135.	6.5	26
117	The perlecan-interacting growth factor progranulin regulates ubiquitination, sorting, and lysosomal degradation of sortilin. Matrix Biology, 2017, 64, 27-39.	3.6	26
118	Long-acting insulin analogs and cancer. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 436-443.	2.6	26
119	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget, 2016, 7, 39980-39995.	1.8	26
120	Clinical Evolution of Autoimmune Thyroiditis in Children and Adolescents. Thyroid, 2009, 19, 361-367.	4.5	25
121	Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 118522.	4.1	25
122	Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer. Matrix Biology, 2020, 93, 10-24.	3.6	25
123	Insulin Receptor. Trends in Endocrinology and Metabolism, 1997, 8, 306-312.	7.1	24
124	A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer. Cell Adhesion and Migration, 2018, 12, 1-10.	2.7	24
125	Immunostaining for Met/HGF Receptor May be Useful to Identify Malignancies in Thyroid Lesions Classified Suspicious at Fine-Needle Aspiration Biopsy. Thyroid, 2001, 11, 783-787.	4.5	23
126	The Insulin and IGF-I Pathway in Endocrine Glands Carcinogenesis. Journal of Oncology, 2012, 2012, 1-19.	1.3	23

#	Article	IF	Citations
127	Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling. AAPS Journal, 2016, 18, 305-310.	4.4	23
128	The G protein estrogen receptor (GPER) is regulated by endothelin-1 mediated signaling in cancer cells. Cellular Signalling, 2016, 28, 61-71.	3.6	23
129	Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation. Cells, 2019, 8, 1017.	4.1	23
130	Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells. PLoS ONE, 2012, 7, e40148.	2.5	22
131	Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer. Cancers, 2021, 13, 621.	3.7	22
132	False positive 131I total body scan due to an ectasia of the common carotidis. Journal of Endocrinological Investigation, 1993, 16, 207-211.	3.3	20
133	Increased Thyroid Cancer Incidence in Volcanic Areas: A Role of Increased Heavy Metals in the Environment?. International Journal of Molecular Sciences, 2020, 21, 3425.	4.1	20
134	Mechanisms of Progranulin Action and Regulation in Genitourinary Cancers. Frontiers in Endocrinology, 2016, 7, 100.	3.5	19
135	Lymph node location is a risk factor for papillary thyroid cancer-related death. Journal of Endocrinological Investigation, 2018, 41, 1349-1353.	3.3	19
136	Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Gravesâ€™ Ophthalmopathy to Parenteral Corticosteroids. Frontiers in Endocrinology, 2020, 11, 609895.	3.5	19
137	Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4385-4387.	3.6	19
138	Appearance of Antithyroglobulin Antibodies as the Sole Sign of Metastatic Lymph Nodes in a Patient Operated on for Papillary Thyroid Cancer: A Case Report. Thyroid, 2000, 10, 431-433.	4.5	17
139	Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer. Current Pharmaceutical Design, 2017, 23, 3658-3666.	1.9	17
140	Seasonal variations in <scp>TSH</scp> serum levels in athyreotic patients under Lâ€thyroxine replacement monotherapy. Clinical Endocrinology, 2017, 87, 207-215.	2.4	16
141	Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling. Frontiers in Cell and Developmental Biology, 2020, 8, 608412.	3.7	16
142	Thyrocyte HLA class II expression and regulation in relation to thyroid autoimmunity. European Journal of Endocrinology, 1987, 116, S27-S34.	3.7	15
143	The morphometric analysis of cell nuclei from fine needle aspirates of thyroid follicular lesions does not improve the diagnostic accuracy of traditional cytologic examination. Journal of Endocrinological Investigation, 1990, 13, 701-707.	3.3	14
144	Differential expression of mucins 1â€“6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1in situ. Journal of Pathology, 2003, 200, 357-369.	4.5	14

#	Article	IF	Citations
145	Sex Steroids Upregulate the IGFâ€1R in Prostate Cancer Cells through a Nongenotropic Pathway. Annals of the New York Academy of Sciences, 2009, 1155, 263-267.	3.8	14
146	Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells. Cells, 2021, 10, 3145.	4.1	14
147	Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. Molecular Endocrinology, 1993, 7, 1667-1676.	3.7	13
148	Efficacy of Botulinum Toxin <scp>A</scp> for Treating Cramps in Diabetic Neuropathy. Annals of Neurology, 2018, 84, 674-682.	5.3	12
149	Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas. Thyroid, 2020, 30, 290-299.	4.5	11
150	Elisa Detection of Salivary Levels of Cd44sol as a Diagnostic Test for Laryngeal Carcinomas. Journal of Cancer Science & Therapy, 2012, 04, .	1.7	10
151	Prognostic role of salivary <scp>CD</scp>44sol levels in the followâ€up of laryngeal carcinomas. Journal of Oral Pathology and Medicine, 2014, 43, 276-281.	2.7	10
152	Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. Pediatric Blood and Cancer, 2018, 65, e27226.	1.5	10
153	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541984640.	2.0	10
154	Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny. Endocrine-Related Cancer, 2019, 26, 713-725.	3.1	10
155	Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. Journal of Chemotherapy, 2019, 31, 150-159.	1.5	9
156	DDR1 Affects Metabolic Reprogramming in Breast Cancer Cells by Cross-Talking to the Insulin/IGF System. Biomolecules, 2021, 11, 926.	4.0	9
157	Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. Journal of Translational Medicine, 2022, 20, .	4.4	9
158	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. Cancer Prevention Research, 2021, 14, 963-972.	1.5	8
159	Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	8
160	Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity. Endocrinology, 1996, 137, 4100-4107.	2.8	8
161	Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis. Current Pharmaceutical Design, 2013, 19, 5344-5361.	1.9	8
162	Ultrasound scanning assessment of L-Thyroxine treatment effectiveness in a group of children with diffuse goiter. Journal of Endocrinological Investigation, 1991, 14, 675-678.	3.3	7

#	Article	IF	Citations
163	Analysis of Progranulin-Mediated Akt and MAPK Activation. Methods in Molecular Biology, 2018, 1806, 121-130.	0.9	7
164	Editorial: Clinical and Molecular Epidemiology of Thyroid Cancer of Follicular Origin. Frontiers in Endocrinology, 2018, 9, 67.	3.5	7
165	Discoidin Domain Receptor 1 functionally interacts with the IGF-I system in bladder cancer. Matrix Biology Plus, 2020, 6-7, 100022.	3.5	7
166	Targeting the Insulin-Like Growth Factor (IGF) System Is Not as Simple as Just Targeting the Type 1 IGF Receptor. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 599-604.	3.8	7
167	Grand Challenges in Cancer Endocrinology: Endocrine Related Cancers, an Expanding Concept. Frontiers in Endocrinology, 2013, 4, 141.	3.5	6
168	Insulin Receptor Isoforms Differently Regulate Cell Proliferation and Apoptosis in the Ligand-Occupied and Unoccupied State. International Journal of Molecular Sciences, 2021, 22, 8729.	4.1	6
169	Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets, 2022, 26, 513-535.	3.4	6
170	Growth Inhibition of Human Endothelial Cells by Human Recombinant Tumor Necrosis Factor Alpha and Interferon-Gamma. Tumori, 1994, 80, 301-305.	1.1	5
171	Epithelial Expression of HLA Class II Molecules: A New Pathogenic Factor in Organâ€Specific Autoimmunity. Acta Medica Scandinavica, 1987, 221, 79-83.	0.0	5
172	Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role. Cancer Biomarkers, 2016, 16, 275-280.	1.7	5
173	Thyroidectomy as Treatment of Choice for Differentiated Thyroid Cancer. International Journal of Surgical Oncology, 2019, 2019, 1-7.	0.6	5
174	Role of thyrotrophin-releasing hormone in the development of pituitary-thyroid axis in four anencephalic infants. European Journal of Endocrinology, 1982, 101, 538-541.	3.7	4
175	Early occurrence of a thyroid carcinoma in a patient who developed Gravesâ€™ disease after treatment for Hodgkinâ€™s disease. Journal of Endocrinological Investigation, 1995, 18, 869-871.	3.3	4
176	Insulin autoimmune syndrome misdiagnosed as an insulinoma in a woman presenting with a pancreatic cystic lesion and taking alpha lipoic acid: a lesson to be learned. Hormones, 2021, 20, 593-595.	1.9	4
177	Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. Frontiers in Endocrinology, 2020, 11, 367.	3.5	4
178	High incidence of anti-GH antibodies in subjects treated with the GH clinical preparation available in Italy. Journal of Endocrinological Investigation, 1980, 3, 313-315.	3.3	3
179	Estrogen receptor variant ERÎ±46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancerâ€associated fibroblasts. Clinical and Translational Medicine, 2021, 11, e516.	4.0	3
180	Obesity, Diabetes, and Cancer: The Role of the Insulin/IGF Axis; Mechanisms and Clinical Implications. Biomolecules, 2022, 12, 612.	4.0	3

#	Article	IF	Citations
181	IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis. Trends in Endocrinology and Metabolism, 2022, 33, 569-586.	7.1	3
182	New insights on the Intrinsic, Pro-Apoptotic Effect of IGFB3 in Breast Cancer. Frontiers in Endocrinology, 2014, 5, 176.	3.5	2
183	Response to Letter to the Editor: â€œTime to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomesâ€. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5110-5111.	3.6	2
184	Onset of Marine-Lenhart syndrome and Gravesâ€™ ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. Hormones, 2021, 20, 161-165.	1.9	2
185	Transition from Cold to Hot Thyroid Nodules. Thyroid, 1997, 7, 897-900.	4.5	1
186	IGF-I and Insulin Receptor Families in Cancer. Energy Balance and Cancer, 2011, , 243-268.	0.2	1
187	HLA Class II Gene Expression in Human Thyroid Cells. Experimental and Clinical Endocrinology and Diabetes, 1992, 100, 17-21.	1.2	0
188	MP61-13 PROGRANULIN TARGETING IN UROTHELIAL CANCER CELLS INHIBITS MOTILITY, ANCHORAGE-INDEPENDENT GROWTH, TUMOR FORMATION IN VIVO AND SENSITIZES CELLS TO CISPLATIN. Journal of Urology, 2016, 195, .	0.4	0
189	Overlaps Between the Insulin and IGF-I Receptor and Cancer. , 2012, , 263-278.		0
190	The IGF-I Axis in Prostate Cancer: The Role of Rapid Steroid Actions. , 2012, , 193-212.		0
191	Abstract 4415: Discoidin domain receptor 1 (DDR1) and IGF-I system crosstalk in bladder cancer progression. , 2014, , .		0
192	Abstract 4945: A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. , 2015, , .		0
193	Abstract 4612: In breast cancer cells IGF-I induces upregulation of DDR1 by suppressing miR-199a-5p via the PI3K/Akt pathway. , 2016, , .		0
194	Abstract 698: Progranulin targeting in urothelial cancer cells inhibits motility, tumor growthin vitroandin vivoand sensitizes cells to cisplatin. , 2016, , .		0
195	Abstract 1344: Progranulin promotes ubiquitination, sorting and lysosomal degradation of sortilin in castration-resistant prostate cancer cells. , 2017, , .		0
196	Cholesterol and Gravesâ€™ Orbitopathy (GO): â€˜A new decision-making algorithm based on baseline low density lipoprotein cholesterol (LDLc) and early GO clinical response to parenteral corticosteroidsâ€™. Endocrine Abstracts, 0, , .	0.0	0